Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Ubicación

MS status

Recruitment Status

Fase

Drogas

Inmunoterapia previa permitida

NCT ID

Title key word search

Fecha en que se añadió el juicio

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Fase	Date Added	Ubicación	Prior IO Allowed	CRC-directed	Status	Drogas	Etiquetas
NCT ID NCT04776148	TitleStudy of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)	Fase Fase 3	Date Added 2021-03-01	Ubicación California, United States Georgia, United States Illinois, United States Maryland, United States Michigan, United States Montana, United States Oregon, United States Pennsylvania, United States Virginia, United States Washington, United States Argentina Australia Canadá China Dinamarca Alemania Israel Japón Corea, República de Russian Federation España Taiwán Turkey Reino Unido	Prior IO Allowed No	CRC-directed Sí	Status Activo, no recluta	Drogas Lenvatinib, Pembrolizumab, Regorafenib, TAS-102 (trifluridine and tipiracil)	Etiquetas MSS/ MMRp
NCT ID NCT03947385	TitleEstudio de IDE196 en pacientes con tumores sólidos portadores de mutaciones GNAQ/11 o fusiones PRKC	Fase Phase 1, Phase 2	Date Added 2019-05-13	Ubicación California, United States New York, United States North Carolina, United States Ohio, United States Pennsylvania, United States Tennessee, United States Texas, United States Australia Canadá	Prior IO Allowed No	CRC-directed Sí	Status Reclutamiento	Drogas Binimetinib, Crizotinib, IDE196	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05838768	TitleStudy of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.	Fase Fase 1	Date Added 2023-05-03	Ubicación California, United States Massachusetts, United States New York, United States Texas, United States Bélgica China Francia Alemania Israel Italia Japón Corea, República de Noruega Singapur España Suecia Taiwán Reino Unido	Prior IO Allowed No	CRC-directed Sí	Status Reclutamiento	Drogas HRO761, Irinotecan	Etiquetas MSI-H/ MMRd
NCT ID NCT04092673	TitleEstudio de eFT226 en sujetos con tumores sólidos malignos avanzados seleccionados	Fase Fase 1	Date Added 2019-09-17	Ubicación California, United States Michigan, United States Nevada, United States New Jersey, United States New York, United States Ohio, United States Texas, United States Virginia, United States	Prior IO Allowed No	CRC-directed No	Status Reclutamiento	Drogas eFT226, eFT226	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03069469	TitleEstudio de DCC-3014 en pacientes con tumores avanzados y tumor tenosinovial de células gigantes	Fase Phase 1, Phase 2	Date Added 2017-03-03	Ubicación California, United States Colorado, United States Florida, United States Massachusetts, United States New York, United States Oregon, United States Tennessee, United States Australia Canadá Francia Italia Países Bajos Polonia España Reino Unido	Prior IO Allowed Sí	CRC-directed No	Status Activo, no recluta	Drogas DCC-3014	Etiquetas MSS/ MMRp
NCT ID NCT03545815	TitleEstudio de células CAR-T mediadas por CRISPR-Cas9 con genes PD-1 y TCR knocked out dirigidos a mesotelina en pacientes con tumores sólidos múltiples mesotelina positivos.	Fase Fase 1	Date Added 2018-06-04	Ubicación China	Prior IO Allowed Sí	CRC-directed No	Status Reclutamiento	Drogas células CAR-T anti-mesotelina	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03950154	TitleEstudio de la combinación de quimioterapia con inmunoterapia celular autóloga en el cáncer colorrectal recidivante y metastásico	Fase Fase 3	Date Added 2019-05-15	Ubicación China	Prior IO Allowed No	CRC-directed Sí	Status Reclutamiento	Drogas Bevacizumab Injection [Avastin], capecitabine, oxaliplatin, PD1-T cells	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03170960	TitleStudy of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors	Fase Fase 1	Date Added 2017-05-31	Ubicación Arizona, United States California, United States Colorado, United States Connecticut, United States District of Columbia, United States Florida, United States Georgia, United States Illinois, United States Kansas, United States Kentucky, United States Louisiana, United States Massachusetts, United States Michigan, United States Minnesota, United States Missouri, United States Nebraska, United States Nevada, United States New Jersey, United States New York, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States South Carolina, United States Texas, United States Utah, United States Virginia, United States Australia Bélgica Francia Alemania Italia Países Bajos España Reino Unido	Prior IO Allowed Sí	CRC-directed Sí	Status Activo, no recluta	Drogas Atezolizumab, Cabozantinib	Etiquetas MSS/ MMRp
NCT ID NCT04963283	TitleStudy of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer	Fase Fase 2	Date Added 2021-07-15	Ubicación Colorado, United States	Prior IO Allowed No	CRC-directed Sí	Status Activo, no recluta	Drogas Cabozantinib, Nivolumab	Etiquetas MSS/ MMRp
NCT ID NCT05198934	TitleSotorasib y panitumumab frente a la elección del investigador para participantes con sarcoma de rata de Kirsten (KRAS) con mutación p.G12C (CodeBreak 300)	Fase Fase 3	Date Added 2022-01-20	Ubicación Alabama, United States California, United States District of Columbia, United States Florida, United States Georgia, United States Michigan, United States New York, United States North Carolina, United States Ohio, United States Pennsylvania, United States Tennessee, United States Texas, United States Australia Francia Alemania Greece Italia Japón Corea, República de Mexico España Taiwán Reino Unido	Prior IO Allowed Sí	CRC-directed Sí	Status Activo, no recluta	Drogas	Etiquetas MSI-H/ MMRd, MSS/ MMRp

Showing 51 to 60 of 299 entries